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Background: A new model of complex diabetes care is provided by a multidisciplinary team which incorporates
general practitioner (GP) Clinical Fellows supported by an Endocrinologist and diabetes educator within a
community-based general practice setting. This study evaluates the health and clinical benefits of the new model
of care, assesses the acceptability of the model to patients, GPs and other health professionals, and examines the
cost-effectiveness of the model.
Methods/Design: The study is an open, non-inferiority randomised controlled trial with data collected at baseline, 6
and 12 months. Participants are identified from new patients on hospital-based diabetes outpatient clinic waiting lists
and new GP referrals. Eligible consenting patients are randomised to either a community practice site (intervention) or
a hospital site (usual care). In the intervention model, medical care is led by a GP Clinical Fellow in partnership with an
Endocrinologist. Quantitative measures include clinical indicators with HbA1c as the primary outcome; patient-reported
outcomes include health-related quality of life, mental health and satisfaction with care. Qualitative methods will be
used to explore the perspectives and experiences of patients and providers regarding the new model of care.
An economic evaluation will also be undertaken.
Discussion: This model of care seeks to improve the quality and safety of healthcare at the interface between the
hospital and primary care sectors for patients with complex diabetes. The study will provide empirical evidence about
the impact of the model of care on health outcomes, patient and clinician satisfaction, as well as any economic impacts.
Trial registration: Clinical Trials Registry Number: ACTRN12612000380897
Keywords: Type 2 diabetes mellitus, Model of care, Randomised controlled trial, Intervention, Usual careBackground
Type 2 diabetes mellitus (T2DM) is one of the most
common chronic diseases and significantly impacts
healthcare systems in both the developed and developing
world. Diabetes currently affects about 371 million
people worldwide [1] and this figure is expected to
increase to 522 million by 2030 [2]. In 2012, 11.7% of
adult Australians were estimated to have diabetes. This
prevalence is increasing steadily, being the fourth most* Correspondence: jenny.zhang@uq.edu.au
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reproduction in any medium, provided the orfrequently managed chronic disease in general practice,
accounting for 6.8% of all chronic disease-related GP visits
[3]. Internationally, waiting lists at specialist diabetes out-
patient departments continue to grow, resulting in
care that can be fragmented and inefficient [4-8]. All
indications are that Australia faces similar challenges
with long waiting lists and difficulties related to accessing
hospital-based diabetes outpatient clinics [9-11]. It follows
that diabetes is a chronic disease where the GP has a
central role to play.
With appropriate support, follow-up and information
technology systems, delivery of complex diabetes care inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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outpatient care [12]. The United Kingdom has introduced
diabetes clinics conducted by general practitioners with
special interests (GPwSIs) with demonstrated favourable
improvements in HbA1c, cholesterol and blood pressure
[13]. This research has demonstrated the potential of
GPwSIs to take on a much greater role in diabetes
screening and management to help meet the current
demands on hospital outpatient services [14-17]. In
addition, an evaluation of a diabetes management program
based on integrated care and management between GPs
and GPwSIs undertaken in Germany showed a reduction
in HbA1c from baseline [18]. Similar studies in Belgium
and the USA have also demonstrated improved outcomes
(HbA1c, systolic blood pressure and LDL-cholesterol) for
diabetes patients using shared or integrated care between
GPs and specialists [19-21]. A multidisciplinary and coor-
dinated approach to diabetes care including collaboration
between practitioners can result in effective, efficient
service delivery [17,22].
Recently in Australia, Russell and colleagues [23] evalu-
ated a model of complex diabetes care using a controlled
pre-post study design which incorporated the principle of
a GPwSI supported by an Endocrinologist and diabetes
educator within a community-based general practice
setting. The study showed promising results with a trend
to better glycaemic control at a reduced delivery cost for
the intervention group compared to the usual care group
treated at a hospital diabetes outpatient clinic. Few studies
have evaluated integrated diabetes services between pri-
mary care and secondary care by increasing the capacity
of primary care to meet the needs of patients who would
otherwise use hospital outpatient services. Even fewer
have done this using randomised controlled trials. Indeed,
a recent systematic review in the area concluded that
there is a need to improve the design and quality of
studies investigating shared care at the primary-secondary
interface [24].
The specific purpose of the work reported here is to
build on the promising results of Russell and colleagues’
study by using a more rigorous study design [23]. The
aim of the study is to evaluate the new model of care
using a range of outcomes, the primary one being
glycaemic control. Secondary outcomes include: other
clinical outcomes; patient-reported outcomes, such as
quality of life and mental health; the acceptability of
the model to patients, GPs and other healthcare providers;
and the cost-effectiveness of the model.
Methods/Design
Study design
The study uses a non-inferiority randomised controlled
trial design. A mixed methods approach of data collection
including quantitative and qualitative methods is used.Non-inferiority trials are designed to show that a novel
treatment is at least no worse than a standard treatment
in terms of some primary clinical endpoint [25], in
this case HbA1c. Accordingly, the primary hypothesis
is that glycaemic control of patients with T2DM who
have their treatment delivered through management
by a community-based multidisciplinary integrated primary-
secondary healthcare team (including an Endocrinologist)
using protocol driven care, will be comparable to glycaemic
control achieved in a hospital outpatient clinic setting.
The research questions include:
1. What is the impact of the new model of care on
glycaemic control and other clinical indicators
compared to usual care?
2. What is the impact of the new model of care on
patient-reported outcomes compared to usual care?
3. What is the cost-effectiveness and cost utility of the
new model of care compared to usual care?
4. What are the perspectives and experiences of
patients and health professionals regarding the new
model of care?
Study settings
There are five study sites located in the southern area of
Brisbane, Australia. The intervention will be administered
in three community-based complex diabetes services. Usual
care will be delivered at two hospital diabetes outpatient
clinics.
Participants
Patients with complex and/or uncontrolled T2DM will
be eligible to participate, and will be recruited from
the two hospital diabetes outpatient clinics. Potential
participants will be identified from patients who are
on the current waiting list at each hospital clinic and
consecutive new patients who are referred to these clinics.
Inclusion and exclusion criteria
Patients with T2DM will be eligible if, on receipt of
referral, they are medically triaged to the most urgent
assigned Category 1 or less urgent Category 2 complex
diabetes patients as defined by the local health department
guidelines (see Additional file 1), aged 18 years or older,
referred as a new patient in the last 12 months, and living
in one of three eligible catchment areas defined by
the boundaries of the three community-based complex
diabetes services.
Patients will be excluded if they attended one of the
study hospital clinics in the previous 12 months for
complex T2DM; or if they are pregnant, on haemodialysis,
a renal transplant recipient, on a waiting list for transplant,
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give informed consent.
Recruitment and randomisation
Research staff located at each participating hospital
will contact eligible patients by telephone to introduce
the study, confirm eligibility, gain verbal consent for
participation and confirm patients’ contact details. Urgent
(Category 1) patients will be contacted as a priority so
they can be seen within 1 to 2 weeks of referral. Eligible,
interested patients will be sent an Introductory Letter, a
Participant Information Sheet and a Consent Form.
Patients who wish to participate will be asked to sign
and return the Consent Form by post or email. Patients
who refuse to participate will be treated at the hospital
diabetes outpatient clinics.
After consent, each participant will be randomly allocated
to the intervention or usual care group, facilitated by
an online computerised centralised allocation process.
Participants will be randomly assigned to the intervention
or usual care group using a computer-generated random
number sequence with an allocation ratio of 3:1 interven-
tion to usual care. Randomisation will be conducted
remotely and in advance, by the study statistician, who is
blinded to the identity of participants. Participants will be
stratified by catchment area for randomisation, and then
will be randomised to either a community-based complex
diabetes services site (intervention) or a hospital site
(usual care). Allocation to group will be concealed to the
researcher during the recruitment and consenting process.
The researcher will access the secure website after
the patient has provided written consent to obtain
the participant’s group allocation.
Once randomised, patients will be notified of their
appointment details by standard practice (that is, letter).
The detailed recruitment steps are shown in Figure 1.
Intervention
Details of the intervention model for the complex diabetes
service have been reported previously [26,27]. Care in the
intervention arm is provided by a multidisciplinary team
consisting of an Endocrinologist, advanced-skilled GPs
(known as Clinical Fellows), a credentialed diabetes educa-
tor and a podiatrist all located together in a community-
based complex diabetes service. Additional allied health
staff (for example, dietician, psychologist) are accessed on
referral depending on patient need. The Clinical Fellows
are experienced local GPs who have undertaken additional
postgraduate education in advanced diabetes care, via the
Master of Medicine (GP) online curriculum. This training
and integrated care guidelines underpins of the model of
care in the community-based clinic.
During their first visit to the complex diabetes service,
patients undertake a comprehensive screening assessmentby a credentialed diabetes educator (care-coordinator),
following a set protocol as outlined in the diabetes
management guidelines, which are evidenced-based guide-
lines including a detailed medical management and lifestyle
management plan [27]. This includes a review of medica-
tions, diabetic history, ensuring retinal screening has been
performed, foot assessment, depression screen and appro-
priate blood and urine testing, prior to booking for the next
available medical appointment at the next available clinic.
Clinics are one-half day in duration and occur every week;
they involve one Endocrinologist, two to three Clinical
Fellows and a diabetes educator.
During the medical appointment, patients are first
assessed by one of the Clinical Fellows, who clarifies the
history, examines the patient and interprets pathology
results. With the patient, the Clinical Fellow drafts a
management plan addressing glycaemic control, blood
pressure, lipids, lifestyle, diabetes complication manage-
ment and the patient’s priorities. The plan is then discussed
with the attending Endocrinologist, who briefly co-consults
with the patient and Clinical Fellow together to finalise the
plan. This allows the Endocrinologist to reduce time spent
with each patient, and to see two to three times the number
of patients per clinic than possible via the traditional
outpatient model. Patients initiating or altering insulin
regimens are enrolled in the Insulin Stabilisation Service,
where patients are contacted by phone twice weekly by the
diabetes educator regarding insulin adjustment, according
to defined guideline protocols. These insulin dosage adjust-
ments are reviewed by a Clinical Fellow or Endocrinologist
within the week. The patient’s GP is kept closely informed
of all care management, and patients are discharged back
to the care of their usual GP once glycaemic, blood
pressure and lipid targets have been achieved. Patients
continue to attend the clinic, but are discharged if there
is no evidence of ongoing improvement following the
12-month review. The GP is advised to continue the usual
cycle of care and is given some parameters for future
re-referral of that individual patient.
Usual care
Care in the usual care arm is provided in a hospital
diabetes outpatient clinic. The patient’s chart is prepared
and the patient then attends a ‘complication screening’
visit performed by a diabetes nurse educator (DNE) to
provide education to the patient and facilitate accurate
triaging of diabetes patients on the clinic waiting list. One
week before the appointment, the patient is phoned
to ensure they have received their appointment letter
and to confirm their contact details.
Appointments are mailed to patients as they become
available. The patient has an initial assessment with the
Endocrinologist or clinic doctor, with correspondence
regarding the management plan communicated to the
Figure 1 Recruitment flow chart.
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clinic as determined by the treating Endocrinologist. An
insulin stabilisation service conducted by the DNE is
also offered to the patient if required.Quantitative study data
Figure 2 displays the study procedure. Quantitative data
collection will include: (1) clinical data extracted from
the diabetes clinics’ databases; and (2) patient-reported
outcomes collected via patient surveys. These data will
be collected at baseline, 6 and 12 months. Clinical data
will be extracted every 6 months from the clinics’ databases
by a research project officer. General practice records will
be relied on for missing clinical data. The surveys will be
distributed to patients before they attend their medical
appointment by the DNE at each site. All quantitative datawill be stored centrally at the university research office in a
purpose-designed password-protected web-based database.Patient demographics
Demographic characteristics recorded include age, sex,
Aboriginal or Torres Strait Islander status, language
spoken at home, and length of time since diagnosis,
household income, educational attainment and employment
status. The data are partially collected from clinical records
and partially from patient survey.Clinical indicators
The primary endpoint is glycaemic control as measured
by the mean change in HbA1c.
The other main clinical indicators include: blood
pressure; serum cholesterol; high-density lipoprotein
Figure 2 Study procedure of the T2DM Research Project.
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creatinine; and estimated glomerular filtration rate (eGFR).
Medications, diabetes complications, smoking status and
body mass index will be recorded. In addition, health
services use information, date of discharge from clinic if
applicable and allied health referrals will be collected.
Patient-reported outcomes
We will measure patients’ quality of life and self-
management, determine the levels of anxiety and depres-
sion that a patient is experiencing, and measure how
satisfied patients are with the service that they receive.
The following standardised scales are used:
(1) The Australian version of the SF-12v2® Health Survey
is a shorter version of the SF-36v2® Health Survey
(The Short Form (36) Health Survey is a survey of
patient health) that uses only 12 items to measure
functional health and wellbeing from the patient’s
point of view [28].
(2) The Diabetes Quality of Life Scale (DQoL-brief ) is a
15-item Brief Clinical Inventory which provides a
total health-related quality of life score that predicts
self-reported diabetes care behaviours and satisfaction
with diabetes control as effectively as the full versionof the instrument. In addition, it provides a vehicle for
quickly screening patients for readiness and specific
treatment-related concerns. It can be used to identify
quality of life issues that might not arise during the
typical patient-provider encounter [29].
(3) The Hospital Anxiety and Depression Scale (HADS)
is a 14-item scale that generates ordinal data. Seven
of the items relate to anxiety and seven relate to
depression. This measure was created specifically
to avoid reliance on aspects of these conditions
that are also common somatic symptoms of illness
(for example, fatigue and insomnia or hypersomnia).
The tool is designed to detect anxiety and depression
in people with physical health problems [30].
(4) The Client Satisfaction Questionnaire (CSQ-8) is
used to measure patient general satisfaction across
health services utilisation. It includes eight items
with good psychometrics, high client and staff
acceptability, and sensitivity to different levels of
program quality [31]. The CSQ-8 will only be
included in the survey at 6 and 12 months.
(5) The Self-management Support Scale [32] is an
important component of improving chronic care
delivery. It has five items and will only be used at
the 6- and 12-month data collection points.
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and diabetes complications will also be measured in
the patient survey.
Economic indicators
Direct and indirect costs for each patient will be measured
using a four-item access to care scale in the patient
survey [16]. This includes some non-medical direct
costs (such as parking and transport) and indirect costs
(such as waiting time and time lost to paid work for both
patient and/or carer). Direct medical costs will include
resource use and service costs, comprising staff costs
(for example, consultant, diabetes educator/DNE and so on),
other service costs for allied health, infrastructure
costs (overheads including rental, utilities, IT support)
and attendance information. The economic evaluation
will comprise a cost-effectiveness analysis and a cost-utility
analysis. The costs for the patient will be measured over
the 12-month period of the study.
Qualitative study data
The qualitative component incorporates: (1) semi-structured
interviews with patients; (2) focus groups with health
providers; and (3) semi-structured interviews with key
organisational stakeholders. Qualitative data will be
collected within the first 3 months and at 12 months.
The qualitative data sample, aims and data collection
methods are presented in Table 1. Approximately 30
to 40 intervention group patients will be purposively
selected across the study sites, based on key dimensions to
ensure information-rich cases that are typical of patients
with T2DM. In this case, sampling will be based on
two key dimensions: level of HbA1c and age of onset of
diabetes, and aim to include a balance of male and female
participants. Beyond these main criteria the intention is to
sample for diversity based on other factors (for example,
socioeconomic status, health insurance status). Participants
will be excluded as potential interviewees if too unwell to
manage a 30- to 45-minute interview, if hospitalised or if
unable to undertake an interview for other reasons. All
potential interviewees will be contacted by phone to
confirm that they are willing to participate and are
available for interview. If interested, a mutually suitable
date and time will be arranged and a copy of the interviewTable 1 Summary of qualitative data collection
Sample Aim
Purposive sample of intervention
group participants
Explore experiences of current care
and perceptions of intervention m
Site-specific groups of multidisciplinary
health professionals
Explore implementation of model
contextual factors impacting delive
Site-specific key stakeholders at
organisational and strategic levels
Explore implementation of model
factors impacting delivery and sustguide will be offered to enable the interviewee to prepare.
At each community site, all health professionals involved
in the management of patients with T2DM under the
new model of care will be invited to participate in a
site-specific focus group, including all GP Clinical Fellows
and specialists, allied health and nursing personnel. At
each intervention site, one key organisational stakeholder
with a management and/or strategic level responsibility
within the practice will be identified and invited to
participate in a semi-structured interview.
An interview guide of open-ended questions will be
used to explore patients’ expectations, perceptions and
experiences of receiving the intervention model of care.
Likewise, open-ended questions will also be used to explore
health professionals’ and key stakeholders’ experiences of
implementing the model of care and their perspectives on
its benefits and sustainability.
Sample size and power calculation
Sample size is based on the primary endpoint of HbA1c
using an alpha = 0.05 and power = 80%. Based on findings
from the pilot study, the sample size calculation used
a pooled standard deviation in HbA1c of 1.7%. The
non-inferiority margin is −0.4% and the true difference
between the groups in HbA1c at 12 months is pre-
dicted to be 0.1% [26]. A randomisation ratio of 3:1
(intervention to usual) has been chosen so that the
clinics at the intervention sites maintain reasonable and
sustainable capacity [16]. Based on the above assumptions
and adding a level of attrition of 20% between baseline
and 12-month follow-up in both groups, the total sample
size is estimated at 456.
Statistical analysis plan
Baseline demographic, psychosocial and clinical character-
istics of participants will be summarised and compared for
differences between the intervention and usual care groups.
Characteristics of participants who complete and those
who withdraw will be compared.
The analysis of the primary outcome (HbA1c) will
be assessed using linear regression; secondary out-
comes measures will be assessed using either linear
regression (continuous outcomes) or logistic regression
(binary outcomes). To adjust for potential between-groupData collection
and expectations
odel
Interview guided by open-ended questions
within first 3 months, and at 12 months
of care and
ry and sustainability
Focus groups guided by open-ended questions
within first 3 months, and at 12 months
of care and contextual
ainability
Interview guided by open-ended questions
within first 3 months, and at 12 months
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will be included as a covariate in models. Site allocation
will also be included in models as a covariate.
All analyses will be conducted on an intention-to-treat
basis. Statistical significance will be based on two-tailed
tests, with P <0.05 considered significant.
Qualitative data analysis
All interviews and focus groups will be conducted by
experienced qualitative researchers and audio-taped for
transcription. The transcripts will be analysed thematically
[33] to identify themes and patterns in order to understand
and illustrate the expectations, perceptions and experiences
of patients and health professionals who use the
intervention model of care. Deviant and negative cases
will be included and all themes will be verified through
constant comparison and team discussion.
Ethics
The study has been granted ethical approval by the
Human Research Ethics Committee of Metro South
Health Service District, Centres for Health Research of
Princess Alexandra Hospital and the Medical Research
Ethics Committee at The University of Queensland.
Discussion
We present a protocol for the study design and methods
to evaluate a new model of diabetes care in the community
through multidisciplinary collaboration and integration
across the primary-secondary interface. The model of care
aims to improve the quality and safety of healthcare at the
interface between hospital- and community-based primary
care for patients with complex diabetes. This model has
been pilot-tested in a community chronic disease manage-
ment service, and the results indicated benefits for diabetes
patients in comparison with usual care at the hospital
diabetes outpatient clinic [23,26]. The current study builds
on the promising results of Russell and colleagues’ study
[23] in a larger, more robust research design and addresses
the methodological issues identified in their study which
utilised a non-randomised convenience sampling method.
Non-inferiority randomised controlled trials are usually
conducted on the premise that there is some other advan-
tage of the treatment such as a reduction in waiting list
times, reduced costs or improved access [34].
The study is important because it will provide empirical
evidence about the impact on health outcomes, patient
and clinician satisfaction, and economic outcomes of the
improved integration of services. The results will also help
us to understand the perspectives and experiences of both
patients and health providers regarding the new model of
care. Using a mixed methods approach will enhance
the quality of the findings by enabling us to examine
the model from different perspectives. It will also provideinsights regarding contextual factors affecting the accept-
ability of the model and how it may be implemented in the
future. In addition, selection bias is avoided by randomising
at the level of individual patients.
However, some limitations of the study need to be
considered. Participant retention in this longitudinal
study will be sensitive to patient medical conditions,
patient motivation as well as patient relocation out of
the study area. There may be some patient issues around
willingness to participate if randomly allocated to a
clinic setting that is difficult to attend due to distance
travel cost, and so on. Additionally, self-reported data on
service use may be under-reported [35,36]. Nevertheless,
every effort has been made to present and structure the
patient information sheet and survey for this present
study in a simple and straightforward format. Furthermore
we have conducted pre-testing and pilot studies to refine
the survey in an attempt to minimise item non-response
and facilitate a good overall response rate [37]. In addition,
efforts will be also made through rigorous implementation
of recruitment and survey strategies during the data
collection process, and using a best-estimation technique
for item non-response to reduce missing items. Also,
we cannot rule out the possibility that change in the
outcomes could in part be accounted for by an obser-
ver effect whereby participants modify their behav-
iour, in particular their self-care and self-management
regimes, in response to being involved in the trial
(for example, the intensity of the study assessment)
rather than in response to being involved in the model of
care. To minimise this effect, we have included both
a control and intervention group in the study design
that undertake the same measures. Patient surveys are
incorporated into the process of patient care, and are
distributed to patients by Registered Nurses at the
clinical study sites for patients to self-complete. Ideally, if
the model of care is shown to be effective and is sub-
sequently embedded in usual clinical practice, routinely
collected clinical data could be used to reassess patient
outcomes in the longer term. Finally, a longer follow-up
period would further elucidate the potential to investigate
the sustainability of any observed effects. The results will
need to be interpreted with consideration of the inherent
weaknesses of non-inferiority trials [25].
There are some challenges around planning and setting
up such a complex randomised controlled trial within a
health services delivery setting, such as governance issues,
the building of relationships with key research stakeholders,
and adjustments to planned research delivery to accommo-
date healthcare reform changes in hospital and community
care. Nevertheless, better integration of primary and
secondary care and ‘ending the blame game’ between
Commonwealth and State-funded healthcare has been
a key element of Australian health reform since 2007.
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comes for communities has been underlined repeatedly by
the National Health and Hospitals Reform Commission,
the Council of Australian Government’s Reform Council,
the National Primary Health Care Strategy, the National
E-Health Transition Authority and Health Workforce
Australia [38]. To date, there have been few rigorous
international publications to guide success in the area.
Our randomised non-inferiority trial, based around a
successful cohort pilot, will progress international learning
in the area of chronic disease. If effective, the intervention
could be applied to other chronic conditions and extended
nationwide for integrated care delivery in the future.
Trial status
Recruitment for the trial began in December 2012. To
date, we have four study sites engaged and 111 patients
recruited (Control: Intervention = 28:83).
Additional file
Additional file 1: Triage categories for diabetes services referrals.
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